Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Shimomura I, Watada H (2016) Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A)
Neurotransmitter inhibiting peptides like Argireline have been examined in the context of expression line appearance
Mol Carcinog
And annual revenue from global obesity drug sales could quadruple to $120 billion by 2030, according to Bloomberg Intelligence